INNT vs. SYRS, VRPX, SCPS, EVLO, CMRA, ARDS, STAB, AMPE, CALA, and PXMD
Should you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Syros Pharmaceuticals (SYRS), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), and PaxMedica (PXMD). These companies are all part of the "medical" sector.
Innovate Biopharmaceuticals vs. Its Competitors
Syros Pharmaceuticals (NASDAQ:SYRS) and Innovate Biopharmaceuticals (NASDAQ:INNT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.
Innovate Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.
Syros Pharmaceuticals presently has a consensus price target of $3.33, indicating a potential upside of 302,930.30%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syros Pharmaceuticals is more favorable than Innovate Biopharmaceuticals.
In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Innovate Biopharmaceuticals'average media sentiment score.
91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 5.9% of Innovate Biopharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Innovate Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Innovate Biopharmaceuticals has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500.
Innovate Biopharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals.
Summary
Syros Pharmaceuticals beats Innovate Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.
Get Innovate Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innovate Biopharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INNT) was last updated on 8/11/2025 by MarketBeat.com Staff
MarketBeat All Access Sale